stockrowNordicus Partners Corporation
NORD Healthcare Biotechnology
Nordicus Partners Corporation’s revenue for fiscal 2025 (year ended March 2025) was $5,000.00, up 100.0% from fiscal 2024.
- Revenue
- −99.6%
- EPS
- −85.7%
- Free cash flow
- +62.2%
Quarter to June 2026, against a year earlier
Follow NORD
Alert me
Nordicus Partners Corporation (NORD) EV/Sales
As of 5 November 2026, Nordicus Partners Corporation (NORD) trades at a EV/Sales of 83.8×. Over the past ten years it has ranged from −1.0× (May 2020) to 130× (October 2025); the current reading is higher than 93% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 57.0× | 1,916.36% |
| FY2024 | 2.8× | 213.35% |
| FY2018 | 0.9× | (29.04%) |
| FY2017 | 1.3× | (29.95%) |
| FY2016 | 1.8× | 68.68% |
| FY2015 | 1.1× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2025 | 57.0× | (25.68%) |
| Dec 2024 | 76.7× | 478.05% |
| Sep 2024 | 13.3× | 1,022.41% |
| Sep 2018 | 1.2× | (14.29%) |
| 14 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CRBP Corbus Pharmaceuticals Holdings, Inc. compare | −26.2× |
| CNXU Conexeu Sciences Inc. compare | n/m |
| OKYO OKYO Pharma Limited Sponsored ADR compare | n/m |
| MAIA MAIA Biotechnology, Inc. compare | n/m |
| ACRV Acrivon Therapeutics, Inc. compare | n/m |
| COYA Coya Therapeutics, Inc. compare | 4.5× |
| NTRB Nutriband Inc. compare | 39.3× |
| MNOV MediciNova, Inc. compare | 49.9× |
| NORD Nordicus Partners Corporation | 83.8× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)